Church & Dwight Co., Inc. - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 26, 2008. Church & Dwight Co., Inc. is a large accelerated filer engaged in the manufacture and sale of household and personal care products (Consumer Domestic), personal care products (Consumer International), and specialty chemical products (Specialty Products Division). The company operates globally with significant manufacturing and distribution facilities.
Key Financial Metrics
| Metric | Three Months Ended Sep 26, 2008 | Nine Months Ended Sep 26, 2008 |
|---|---|---|
| Net Sales | $630.7 million | $1,777.5 million |
| Gross Profit | $251.1 million | $717.7 million |
| Gross Margin | 39.8% | 40.4% |
| Net Income | $49.0 million | $150.9 million |
| Diluted EPS | $0.69 | $2.16 |
| Operating Cash Flow (9mo) | $222.1 million | |
| Total Debt | $881.7 million | |
| Cash and Equivalents | $175.7 million | |
| Net Debt | $706.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% in the quarter and 8% for the nine-month period compared to 2007. Growth was driven by the Orajel Acquisition (approx. 4-5% of quarterly growth), price increases, and favorable sales mix, partially offset by the divestiture of the Brotherton subsidiary and foreign exchange impacts.
- Profitability: Gross margin expanded 30 basis points in the quarter and 100 basis points for the nine months due to price increases, cost reduction programs, and higher-margin acquired products. However, operating income for the quarter declined slightly ($85.5M vs $88.6M) due to increased marketing and SG&A expenses.
- Acquisition Impact: The company acquired Del Pharmaceuticals (Orajel) for $383.2 million in July 2008, funded by $250 million in new debt and cash. This added significant goodwill ($182.4M) and intangible assets ($184.0M).
- Debt Structure: The company redeemed all outstanding convertible debentures ($99.9M) in the third quarter, converting them into common stock. This reduced interest expense despite the new debt incurred for the Orajel acquisition.
Outlook, Risks, and Unusual Items
- Plant Shutdown and Expansion: The company announced the closure of its North Brunswick, NJ facility in 2009 and the construction of a new $150 million plant in York County, PA. This resulted in accelerated depreciation charges ($3.5M in Q3) and future severance/exit costs.
- Legal Proceedings: The company won a patent infringement suit against Abbott Laboratories regarding pregnancy test kits, with damages doubled to $29.2 million by the court, though a post-trial motion remains pending.
- Regulatory Risks: Ongoing FDA discussions regarding the labeling of condoms containing nonoxynol-9 (N-9) could impact sales if new restrictions are imposed.
- Market Risks: The company faces exposure to diesel fuel price volatility (hedged partially) and foreign currency fluctuations. A 10% change in exchange rates could impact currency gains/losses by approximately $4.0 million.
- Dividends: Dividends per share increased to $0.09 for the quarter (from $0.08 in 2007) and $0.25 for the nine months (from $0.22 in 2007).
Investor Verification Checklist
- Integration of Orajel: Verify the realization of synergies and margin improvements from the Del Pharmaceuticals acquisition in subsequent quarters.
- Capital Expenditures: Monitor the $150 million capital outlay for the new York County facility and the associated cash flow impact.
- Legal Resolution: Track the final resolution of the Abbott Laboratories litigation and the collection of the $29.2 million award.
- Debt Covenants: Confirm continued compliance with credit facility covenants (Leverage ratio 2.02 vs 3.5 max; Interest coverage 8.85 vs 3.0 min) amidst the credit market environment.
- Commodity Costs: Assess the impact of raw material and energy price fluctuations on future gross margins.